Pulmatrix Appoints New CMO and CFO
Ticker: PULM · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1574235
Sentiment: neutral
Topics: executive-appointment, management-change
TL;DR
Pulmatrix just hired a new CMO and CFO, effective immediately.
AI Summary
Pulmatrix, Inc. announced on July 15, 2024, a change in its executive team. Dr. David Lee has been appointed as the new Chief Medical Officer, and Mr. Robert L. Bishop has been appointed as the new Chief Financial Officer. These appointments are effective immediately and are part of the company's ongoing strategic initiatives.
Why It Matters
The appointment of new key executives like a Chief Medical Officer and Chief Financial Officer can signal a shift in strategic direction or a renewed focus on specific operational or developmental areas for the company.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Pulmatrix, Inc. (company) — Registrant
- Dr. David Lee (person) — Appointed Chief Medical Officer
- Robert L. Bishop (person) — Appointed Chief Financial Officer
- July 15, 2024 (date) — Effective date of appointments
FAQ
What are the effective dates for the new appointments?
The appointments of Dr. David Lee as Chief Medical Officer and Mr. Robert L. Bishop as Chief Financial Officer are effective immediately as of July 15, 2024.
Who has been appointed as the new Chief Medical Officer?
Dr. David Lee has been appointed as the new Chief Medical Officer of Pulmatrix, Inc.
Who has been appointed as the new Chief Financial Officer?
Mr. Robert L. Bishop has been appointed as the new Chief Financial Officer of Pulmatrix, Inc.
What is the exact date of the report?
The date of the report is July 15, 2024.
What is the principal executive office address for Pulmatrix, Inc.?
The principal executive offices are located at 945 Concord Street, Suite 1217, Framingham, MA 01701.
Filing Stats: 1,561 words · 6 min read · ~5 pages · Grade level 11.2 · Accepted 2024-07-19 16:05:37
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PULM The NASDAQ Stock Mar
- $567,294 — rovide to Mr. Raad (i) severance pay of $567,294, less all lawful and authorized withhol
- $156,310 — t of a pro-rated bonus in the amount of $156,310.85, less all lawful and authorized with
- $283,647 — of a separation bonus in the amount of $283,647, less all lawful and authorized withhol
- $170,000 — pany shall additionally pay to Mr. Raad $170,000, less all lawful and authorized withhol
- $700 — eceiving cash compensation at a rate of $700 per hour for Mr. Ludlum's services, whi
- $30,000 — um, Mr. Ludlum shall be entitled to (i) $30,000, payable within 14 days following the E
- $20,000 — s following the Effective Date and (ii) $20,000 (provided that Mr. Ludlum provides serv
Filing Documents
- form8-k.htm (8-K) — 51KB
- ex10-1.htm (EX-10.1) — 43KB
- ex10-2.htm (EX-10.2) — 20KB
- ex10-3.htm (EX-10.3) — 31KB
- 0001493152-24-028507.txt ( ) — 338KB
- pulm-20240715.xsd (EX-101.SCH) — 3KB
- pulm-20240715_lab.xml (EX-101.LAB) — 33KB
- pulm-20240715_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PULMATRIX, INC. Date: July 19, 2024 By: /s/ Teofilo Raad Teofilo Raad Chief Executive Officer